Thomas W. D'Alonzo to Board of Directors Business Editors AMARILLO, Texas--(BUSINESS WIRE)--March 20, 1997--Amarillo Biosciences Inc. (NASDAQ:AMAR) announced today the appointment of Thomas W. D'Alonzo (53) to its Board of Directors. D'Alonzo is president and chief operating officer of PPD Pharmaco Inc., a global contract research organization headquartered in Wilmington, N.C. Previously he had been president of Genvec Inc., a gene therapy biotechnology company. He is a former president of Glaxo Inc. where he spearheaded the company's impressive growth in sales and profits, with Zantac sales passing the $1 billion mark. D'Alonzo holds a law degree from the University of Denver College of Law and a B.S. in Business administration from the University of Delaware. In announcing the appointment, Joseph Cummins, President and Chief Executive Officer of Amarillo, said, "We are pleased with the addition of Tom D'Alonzo to our Board. Mr. D'Alonzo brings with him a significant understanding of the biotech industry. We believe his guidance as a Board Member will be instrumental in helping us to achieve our overall strategic goals." Amarillo Biosciences Inc. is one of the leading companies developing oral interferon alpha as a treatment of a variety of diseases including oral mucositis in cancer patients, Hepatitis B, Hepatitis C and Sjogren's Syndrome.
U.K. July Retail Sales Rise 0.1%; Median Estimate 0.4% Increase
AMARILLO BIOSCIENCES INC. APPOINTS
Press spacebar to pause and continue. Press esc to stop.